Ebastine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ebastine: From Allergic Rhinitis to Coronary Artery Disease
One-Sentence Summary
Ebastine is a second-generation antihistamine, originally used for allergic rhinitis, vasomotor rhinitis and idiopathic urticaria. The TxGNN model predicts it may be effective for coronary artery disease, but no clinical trials and no directly relevant publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, idiopathic urticaria (from the TxGNN knowledge graph; the Singapore licence has no indication text recorded) |
| Predicted New Indication | Coronary artery disease |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Ebastine is known to be a selective H1-receptor antagonist (second generation), and its efficacy in allergic rhinitis and urticaria is established.
Histamine and mast cell activity have been discussed in coronary vasospasm and atherosclerosis, so a theoretical pathway exists. However, this link is speculative. H1 antagonism has not been shown to benefit coronary disease, and the high score is a model prediction only. It may partly reflect network proximity to other cardiac disease nodes rather than true biological rationale.
Other Predicted Indications (Ranks 2–10)
All of the following are supported by model prediction only (L5), with no clinical trials, and all are rated Hold.
| Rank | Predicted Indication | Score | Comment |
|---|---|---|---|
| 2 | Myocardial ischemia | 99.10% | Histamine-mediated coronary vasoconstriction is theoretical only. Ebastine/carebastine has known QT-related considerations, which argue for caution in cardiac patients. |
| 3 | Anomalous left coronary artery from the pulmonary artery | 98.97% | Congenital structural anomaly treated surgically; no plausible pharmacological mechanism. |
| 4 | Leprosy | 98.86% | Only one publication was returned and it concerns levocetirizine, not ebastine. |
| 5 | Candidiasis | 98.72% | No antifungal mechanism established. |
| 6 | Pneumocystosis | 98.69% | No mechanism linking H1 antagonism to infection. |
| 7 | Hypertrichosis | 98.55% | No mechanistic rationale. |
| 8 | Polyp of vocal cord | 98.37% | Tenuous link via allergic/inflammatory upper-airway disease. |
| 9 | Polyp of middle ear | 98.36% | Weak link via mucosal inflammation; usually managed surgically. |
| 10 | Uterine polyp | 98.35% | No plausible mechanism (hormonal, proliferative). |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
For the top-ranked prediction (coronary artery disease), currently no related literature is available.
The only publication returned across all predictions relates to the rank 4 prediction (leprosy), and is not direct evidence for ebastine:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39230196 | 2024 | Review | Expert Review of Clinical Pharmacology | Consensus statement on levocetirizine (a different antihistamine) in chronic spontaneous urticaria; second-generation antihistamines are first-line therapy for this condition. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09435P | KESTINE TABLET 10 mg | Tablet, film coated (oral) | Not recorded in the data compiled for this report |
Safety Considerations
- Cardiac caution (QT): Ebastine and its active metabolite carebastine have known QT-related considerations, which argue for caution in patients with cardiac disease. This is particularly relevant to the cardiovascular indications predicted here.
No drug interaction records were found, and no contraindications are recorded in the knowledge graph. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten predictions are supported by model output alone (L5), with no clinical trials and no directly relevant literature. The top predictions are cardiovascular, where the QT-related considerations of ebastine add a safety concern rather than support.
To proceed, the following is needed:
- Mechanism of action data (MOA) to enable a proper mechanistic-link analysis
- Package insert warnings and contraindications, which are needed before any safety screening
- A systematic literature search specific to ebastine/carebastine and coronary disease or myocardial ischemia (histamine, mast cells, vasospasm)
- A QT and cardiac safety assessment before considering any cardiovascular use
- Preclinical or mechanistic studies to establish a biological rationale for the top-ranked prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.